Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
about
Bioflavonoids as poisons of human topoisomerase II alpha and II betaTargeting DNA topoisomerase II in cancer chemotherapyMms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase IICharacterization of the DNA-binding domain and identification of the active site residue in the 'Gyr A' half of Leishmania donovani topoisomerase IIInhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damageDrugging topoisomerases: lessons and challengesThe identification of a functional interaction between PKC and topoisomerase II.Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid LeukemiaThe ATPase reaction cycle of yeast DNA topoisomerase II. Slow rates of ATP resynthesis and P(i) releaseTopoisomerase II can unlink replicating DNA by precatenane removalVoreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase IINumerical analysis of etoposide induced DNA breaksThe broken MLL gene is frequently located outside the inherent chromosome territory in human lymphoid cells treated with DNA topoisomerase II poison etoposideRole of minor groove width and hydration pattern on amsacrine interaction with DNAToward discovering new anti-cancer agents targeting topoisomerase IIα: a facile screening strategy adaptable to high throughput platformDNA topoisomerase II is essential for preimplantation mouse developmentActivity of Indenoisoquinolines against African TrypanosomesTopoisomerase levels determine chemotherapy responsein vitroandin vivoGammaH2AX and cancerSingle-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors.A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631.DNA-AP sites generation by etoposide in whole blood cells.Werner helicase relocates into nuclear foci in response to DNA damaging agents and co-localizes with RPA and Rad51.Interaction between tumor suppressor adenomatous polyposis coli and topoisomerase IIalpha: implication for the G2/M transition.Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesionsA diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.Cleavage of plasmid DNA by eukaryotic topoisomerase II.Quinone-induced enhancement of DNA cleavage by human topoisomerase IIalpha: adduction of cysteine residues 392 and 405.Biochemical assays for the discovery of TDP1 inhibitorsThe use of divalent metal ions by type II topoisomerases.Evaluating the genotoxicity of topoisomerase-targeted antibioticsMLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomImproved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosisDexrazoxane for the treatment of chemotherapy-related side effects.The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase IDNA topoisomerase II as a target for cancer chemotherapy.
P2860
Q24627367-3C52B9C0-2878-4203-B361-41CAA1B72FDBQ24649711-D3A3E0C4-A0B2-406F-A82A-DF1C54ADD481Q24791392-2CFC83A3-8407-407C-B47E-132EDD1DAB4AQ24793787-899B29F9-283E-4C3B-A9A9-2EBF23D5597AQ25257535-6499CEFF-0037-4EF3-91AF-34AF22555F32Q27000099-879D8733-169B-4DDF-8562-84DD5C6482D4Q27930540-22F03793-70C7-46C8-A72C-200A2F0FC165Q28072058-184ECD61-9C4F-4C7F-903A-1D699F6A00ACQ28189142-D0D7E11E-C252-40F7-B779-5400B24392B2Q28364067-BFBBB75A-027A-4D8D-8B39-EDF26BC08E14Q28473683-665968D0-B1B7-413E-B24C-EABA7DEF229EQ28475598-76C2F30D-D1CF-48C0-8433-B29FA84847D7Q28533804-52F15DEF-C70F-421D-8E0F-ADB161104310Q28534955-EF98B95B-00D8-4DB1-98F5-B50077CCEF2FQ28538627-BE4F04C6-E224-40CE-81B1-F7ECEEA8B51BQ28589046-8391C506-1B2D-4B3A-8D64-1B22D900E58BQ29041290-C945FDD8-FC0F-48B7-9F80-28E8E90C2ABFQ29395563-9D79CFA8-C355-47C0-80EC-4ED825930C95Q29614974-5C5E9B49-E0AF-4F13-9EC1-B3F3FCEA3882Q30673594-E841E1CF-F5F6-4304-A5E5-1892BF67B52CQ30886208-D843B49B-6045-4121-A5AC-289E886607C7Q30886598-5AF41BA8-10C3-44E0-90A9-DF958F5315EAQ30990769-5888DB18-7678-4DA8-8B5B-BC837DD37EC4Q33352443-5E9603A2-E12E-4422-AD6D-CEA8D1140EC2Q33631024-30DCA8F0-0363-4C2F-990A-FFD07EBAF571Q33638364-7F0AB7CB-F78F-4944-8896-262163972EB8Q33807370-A1859867-96CB-4285-8ED0-0C5D8F67D606Q33922870-DE559DBF-1B30-41A2-B360-7C474084574BQ33944673-431B738A-B6C0-4FD5-97E8-C5E0EAFF08BBQ33947475-5E4211FA-A1CD-463F-BA55-EDF75C9453FDQ33957966-2A10AB03-8801-480C-9630-6477BA5ECF15Q34021070-3DCE2156-1DC1-4978-B44B-4A158684D525Q34054930-DEC910E4-5BDE-4CE2-B589-BFAAE986D458Q34095957-4D0D78E4-4DB7-4771-AB5F-3F8D8BF71F3AQ34136814-4EE38C50-1E92-40D0-8169-D9994B80B709Q34139877-5411D31B-A2DB-43A6-8AE3-A87416462B39Q34198047-B6DAD8CA-C83D-42D9-B932-DB54E0AF4893Q34211957-928645F7-EDFD-49CA-A85B-7B90CDBE1B08Q34559593-8B5F2863-907A-417B-B4CA-8AC43DD15D97Q34718447-CC929F9A-202A-4701-83E6-0A672E869EC0
P2860
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
@ast
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
@en
type
label
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
@ast
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
@en
prefLabel
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
@ast
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
@en
P1476
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
@en
P2093
Fortune JM
Osheroff N
P304
P356
10.1016/S0079-6603(00)64006-0
P577
2000-01-01T00:00:00Z